文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

表达IL-15与CD19靶向CAR的脐带血NK细胞表现出长期持久性与强效抗肿瘤活性

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
PubMed 文献 · Leukemia · 2017-07-20

研究将携带CAR-CD19、IL-15及诱导型caspase-9自杀基因(iC9)的逆转录病毒载体转导脐带血来源NK细胞,体外证实可有效杀伤CD19表达细胞系与原代白血病细胞,并在Raji淋巴瘤异种移植小鼠模型中显著延长生存;IL-15产生关键性改善转导细胞功能,iC9药物激活后可迅速清除工程化NK细胞。

要点

  • 脐带血NK细胞经CAR-CD19、IL-15与iC9自杀基因转导后,体外有效杀伤CD19表达细胞系与原代白血病细胞。
  • 在Raji淋巴瘤异种移植小鼠模型中,转导的脐带血NK细胞显著延长生存。
  • IL-15产生关键性改善转导脐带血NK细胞功能,iC9药物激活后可迅速清除工程化细胞。

核心结论

  • 研究开发了基于工程化脐带血来源NK细胞的免疫治疗新方法,易于生产、疗效显著并纳入限制毒性的安全措施。
  • 作者认为该方法应能大幅改善将该疗法提供给大量患者的物流可及性,而这是当前CAR-T细胞疗法的主要限制。

研究设计与样本

  • 研究将携带CAR-CD19、IL-15及诱导型caspase-9自杀基因(iC9)的逆转录病毒载体转导脐带血来源NK细胞。
  • 体外评估对CD19表达细胞系与原代白血病细胞的杀伤,并在Raji淋巴瘤异种移植小鼠模型中评估生存。

主要发现

  • 转导的脐带血NK细胞在体外有效杀伤CD19表达细胞系与原代白血病细胞。
  • 在Raji淋巴瘤异种移植小鼠模型中,转导的脐带血NK细胞显著延长生存。
  • IL-15产生关键性改善转导脐带血NK细胞的功能。
  • iC9/CAR.19/IL-15脐带血NK细胞在iC9自杀基因药物激活后被迅速清除。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptors (CARs) have been used to redirect the specificity of autologous T cells against leukemia and lymphoma with promising clinical results. Extending this approach to allogeneic T cells is problematic as they carry a significant risk of graft-versus-host disease (GVHD). Natural killer (NK) cells are highly cytotoxic effectors, killing their targets in a non-antigen-specific manner without causing GVHD. Cord blood (CB) offers an attractive, allogeneic, off-the-self source of NK cells for immunotherapy. We transduced CB-derived NK cells with a retroviral vector incorporating the genes for CAR-CD19, IL-15 and inducible caspase-9-based suicide gene (iC9), and demonstrated efficient killing of CD19-expressing cell lines and primary leukemia cells in vitro, with marked prolongation of survival in a xenograft Raji lymphoma murine model. Interleukin-15 (IL-15) production by the transduced CB-NK cells critically improved their function. Moreover, iC9/CAR.19/IL-15 CB-NK cells were readily eliminated upon pharmacologic activation of the iC9 suicide gene. In conclusion, we have developed a novel approach to immunotherapy using engineered CB-derived NK cells, which are easy to produce, exhibit striking efficacy and incorporate safety measures to limit toxicity. This approach should greatly improve the logistics of delivering this therapy to large numbers of patients, a major limitation to current CAR-T-cell therapies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2017. PMID: 28725044. doi:10.1038/leu.2017.226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。